UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The approval of Aduhelm risks eroding public trust in Alzheimer research and the FDA

Nature reviews. Neurology, 2021-09, Vol.17 (9), p.523-524

2021

Volltextzugriff (PDF)

Remaining Questions in a Brave New World of Alzheimer's Disease Care

The American journal of geriatric psychiatry, 2024-01, Vol.32 (1), p.55-57

Grill, Joshua D

2024

Volltextzugriff (PDF)

Disclosing Alzheimer Disease Biomarker Results to Research Participants

JAMA neurology, 2022-07, Vol.79 (7), p.645

2022

Volltextzugriff (PDF)

Implications of FDA Approval of a First Disease-Modifying Therapy for a Neurodegenerative Disease on the Design of Subsequent Clinical Trials

Neurology, 2021-09, Vol.97 (10), p.496-500

2021

Volltextzugriff (PDF)

Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials

Alzheimer's research & therapy, 2010-12, Vol.2 (6), p.34-34

2010

Volltextzugriff (PDF)

Testing for Alzheimer Disease Biomarkers and Disclosing Results Across the Disease Continuum

Neurology, 2023-05, Vol.100 (21), p.1010-1019

2023

Volltextzugriff (PDF)

What Should the Goals Be for Diverse Recruitment in Alzheimer Clinical Trials?

JAMA neurology, 2022-11, Vol.79 (11), p.1097

2022

Volltextzugriff (PDF)

Centers for Medicare and Medicaid Services Coverage of Amyloid PET

JAMA neurology, 2024-09, Vol.81 (9), p.903

2024

Volltextzugriff (PDF)

Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer’s disease clinical trials

Neurobiology of aging, 2016-03, Vol.39, p.147-153

2016

Volltextzugriff (PDF)

Frameworks for estimating causal effects in observational settings: comparing confounder adjustment and instrumental variables

BMC medical research methodology, 2023-05, Vol.23 (1), p.122-24, Article 122

2023

Volltextzugriff (PDF)

Direct Mail Recruitment to a Potential Participant Registry

Alzheimer disease and associated disorders, 2021-01, Vol.35 (1), p.80-83

2021

Volltextzugriff (PDF)

Facilitating Alzheimer Disease Research Recruitment

Alzheimer disease and associated disorders, 2014-01, Vol.28 (1), p.1-8

2014

Volltextzugriff (PDF)

Unmet Needs of Caregivers of Individuals Referred to a Dementia Care Program

Journal of the American Geriatrics Society (JAGS), 2015-02, Vol.63 (2), p.282-289

2015

Volltextzugriff (PDF)

Study Partner Type and Adverse Event Reporting in Mild-to-Moderate Alzheimer's Disease Clinical Trials

Journal of Alzheimer's disease, 2024-01, Vol.98 (2), p.729-738

2024

Volltextzugriff (PDF)

Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment

JAMA neurology, 2020-12, Vol.77 (12), p.1504

2020

Volltextzugriff (PDF)

Post‐disclosure distress among racial and ethnic groups in a preclinical AD trial

Alzheimer's & dementia, 2024-04, Vol.20 (4), p.2508-2515

2024

Volltextzugriff (PDF)

Retention of American Indian and Alaska Native participants in the National Alzheimer's Coordinating Center Uniform Data Set

Alzheimer's & dementia, 2024-03, Vol.20 (3), p.1601-1613

2024

Volltextzugriff (PDF)

Estimating attrition in mild-to-moderate Alzheimer's disease and mild cognitive impairment clinical trials

Alzheimer's research & therapy, 2023-11, Vol.15 (1), p.203-203, Article 203

2023

Volltextzugriff (PDF)

Study partners should be required in preclinical Alzheimer's disease trials

Alzheimer's research & therapy, 2017-12, Vol.9 (1), p.93-93, Article 93

2017

Volltextzugriff (PDF)

Economic hardships of Korean American family caregivers of persons with dementia: a mixed-methods study

Aging & mental health, 2023-09, Vol.27 (9), p.1762-1769

2023

Volltextzugriff (PDF)

Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease Trial

JAMA network open, 2021-07, Vol.4 (7), p.e2114364-e2114364

2021

Volltextzugriff (PDF)

Examining Utilization of Formal Supports and Related Impacts on Overall Well-Being Among East Asian American Family Caregivers of Persons With Dementia: A Mixed-Methods Study

The Gerontologist, 2024-02, Vol.64 (2)

2024

Volltextzugriff (PDF)

Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo‐Controlled, Double‐Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease

Annals of neurology, 2024-02, Vol.95 (2), p.288-298

2024

Volltextzugriff (PDF)

Recruitment across two decades of NIH-funded Alzheimer's disease clinical trials

Alzheimer's research & therapy, 2023-02, Vol.15 (1), p.28-28, Article 28

2023

Volltextzugriff (PDF)

Strategies Associated with Retaining Participants in the Longitudinal National Alzheimer's Coordinating Center Uniform Data Set Study

Journal of Alzheimer's disease, 2022, Vol.87 (4), p.1557-1566

2022

Volltextzugriff (PDF)

1 – 25 von 249

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(222)
Mit Volltextzugriff
(195)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

The approval of Aduhelm risks eroding public trust in Alzheimer research and the FDA

Remaining Questions in a Brave New World of Alzheimer's Disease Care

Disclosing Alzheimer Disease Biomarker Results to Research Participants

Implications of FDA Approval of a First Disease-Modifying Therapy for a Neurodegenerative Disease on the Design of Subsequent Clinical Trials

Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials

Testing for Alzheimer Disease Biomarkers and Disclosing Results Across the Disease Continuum

What Should the Goals Be for Diverse Recruitment in Alzheimer Clinical Trials?

Centers for Medicare and Medicaid Services Coverage of Amyloid PET

Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer’s disease clinical trials

Frameworks for estimating causal effects in observational settings: comparing confounder adjustment and instrumental variables

Direct Mail Recruitment to a Potential Participant Registry

Facilitating Alzheimer Disease Research Recruitment

Unmet Needs of Caregivers of Individuals Referred to a Dementia Care Program

Study Partner Type and Adverse Event Reporting in Mild-to-Moderate Alzheimer's Disease Clinical Trials

Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment

Post‐disclosure distress among racial and ethnic groups in a preclinical AD trial

Retention of American Indian and Alaska Native participants in the National Alzheimer's Coordinating Center Uniform Data Set

Estimating attrition in mild-to-moderate Alzheimer's disease and mild cognitive impairment clinical trials

Study partners should be required in preclinical Alzheimer's disease trials

Economic hardships of Korean American family caregivers of persons with dementia: a mixed-methods study

Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease Trial

Examining Utilization of Formal Supports and Related Impacts on Overall Well-Being Among East Asian American Family Caregivers of Persons With Dementia: A Mixed-Methods Study

Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo‐Controlled, Double‐Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease

Recruitment across two decades of NIH-funded Alzheimer's disease clinical trials

Strategies Associated with Retaining Participants in the Longitudinal National Alzheimer's Coordinating Center Uniform Data Set Study

Suchergebnisse filtern